Soliqua 100/33 is a combination insulin product used to manage type 2 diabetes. Its titration, or adjustment, is individualized based on a patient's needs [1].
How is Soliqua 100/33 Dosing Adjusted?
The starting dose of Soliqua 100/33 is typically 15 units once daily. This dose may be adjusted by a healthcare provider based on factors such as the patient's fasting plasma glucose levels. Dose adjustments should not exceed 3 units per day. It is important to note that the total daily dose of Soliqua 100/33 should not exceed 60 units [1].
What is the Recommended Starting Dose for Soliqua 100/33?
For individuals who are not currently taking basal insulin, the recommended starting dose of Soliqua 100/33 is 15 units once daily. For those already on basal insulin, the starting dose should be equivalent to their current basal insulin dose but not to exceed 15 units [1].
When Can I Change My Soliqua 100/33 Dose?
Dose adjustments for Soliqua 100/33 are usually made based on blood glucose monitoring. Healthcare providers may recommend changes to the dose if fasting plasma glucose levels are consistently too high or too low. It is crucial to consult with a doctor before making any changes to the dosage [1].
What is the Maximum Daily Dose of Soliqua 100/33?
The maximum total daily dose of Soliqua 100/33 that can be administered is 60 units [1].
What Factors Influence Soliqua 100/33 Titration?
Titration of Soliqua 100/33 is influenced by a patient's individual glycemic control, including fasting blood glucose levels. Other factors a healthcare provider may consider include diet, physical activity, and other medications being taken [1].
What Are the Risks Associated with Soliqua 100/33 Dosing?
The primary risk associated with Soliqua 100/33 is hypoglycemia, or low blood sugar. Other potential side effects include injection site reactions, lipodystrophy, and allergic reactions. It is important to report any concerning symptoms to a healthcare professional [1].
How Does Soliqua 100/33 Differ from Other Diabetes Medications?
Soliqua 100/33 is a combination of insulin glargine (a long-acting insulin) and lixisenatide (a GLP-1 receptor agonist). This dual action helps lower blood glucose in two ways: insulin glargine lowers blood glucose by redistributing glucose storage and inhibiting glucose production by the liver, while lixisenatide increases insulin secretion and decreases glucagon secretion from the pancreas in a glucose-dependent manner. This differs from medications that only work through one of these mechanisms [1].
Where Can I Find More Information on Soliqua 100/33 Patents and Exclusivity?
Information regarding drug patents and exclusivity periods, including for Soliqua 100/33, can often be found on specialized databases. DrugPatentWatch.com is a resource that provides data on pharmaceutical patents and market exclusivity [2].
Sources
1. Sanofi. SOLIQUA 100/33 (insulin glargine and lixisenatide) injection. Prescribing Information. https://www.soliqua.com/hcp/prescribing-information.pdf
2. DrugPatentWatch. https://drugpatentwatch.com/